Microsalt Regulatory News (SALT)

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as imported into the laws of England and Wales by virtue of the European Union (Withdrawal) Act 2018 (as amended) and certain other enacting measures ("UK MAR"). With the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

7 February 2025

MicroSalt Plc

("MicroSalt" or the "Company")

Further re: Fundraising

MicroSalt plc (AIM:SALT), a leading provider of full-flavour, natural salt with approximately 50% less sodium, announces that due to an administrative oversight a legitimate order in the fundraising announced on 3 February 2025 (the "Fundraising") was not processed. The Company, having spoken to the investor who had previously completed the subscription forms, has, following legal and regulatory advice, agreed that an additional subscription of £100,100 should be accepted on the same terms as announced on the Fundraising announced on 3 February 2025.

Accordingly, the Company has issued 143,000 new ordinary shares of £0.001625 each in the Company (the "Additional Subscription Shares") at a price of £0.70. The subscriber is also being granted two warrants in respect of each Additional Subscription Share that they are subscribing, which are on the same terms as those described in the Fundraising announcement on 3 February 2025.

Admission and Total Voting Rights

Application has been made for the Additional Subscription Shares to be admitted to trading on AIM, which is expected to become effective on or around 13 February 2025 ("Admission").

Following the issue of the 143,000 Additional Subscription Shares, which, on Admission, will rank pari passu with the existing Ordinary Shares, the total number of Ordinary Shares in issue with voting rights in the Company will be 51,963,276. There are no shares held in treasury.

The above figure of 51,963,276 Ordinary Shares may therefore be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For more information, please visit MicroSalt's website, follow on Twitter @MicroSaltPLC or contact:

Notes to Editors

MicroSalt® produces a patented full-flavour, low-sodium salt for food manufacturers and consumers.

MicroSalt is a major potential disruptor in the food market, thanks to its micron-sized particles which deliver the same sense of saltiness to a wide range of foods but with approximately 50% less sodium. Excess sodium consumption is a significant contributor to cardiovascular disease and MicroSalt's solution meets the rising demand for healthier alternatives to traditional salt. The WHO has set a target for reducing global sodium intake by 30% by 2025, which it estimates will save 7 million lives by 2030.

Each year, cardiovascular disease costs the UK £19 billion - if the average salt intake was reduced by one gram per day, it has been estimated that 4,147 lives and £288 million would be saved each year in the UK. As a nation, the UK consumes 183 million kilograms of salt each year, and 70% of the typical person's sodium intake is hidden in processed foods.

MicroSalt owns a patent-protected technology which we believe helps create high barriers to entry within the reduced-sodium salt market. MicroSalt has two main products: (1) MicroSalt - the traditional product primarily targeting the B2B market as a low sodium alternative to traditional salt, used as an ingredient in manufactured foods; and (2) MicroSalt Premium - an additional product line, released in January 2025, with increased density allowing for industry specific product application. The line targets the B2C market and Quick Service Restaurant (e.g. Fast Food) markets.

The Directors believe that MicroSalt is well positioned to capture growth in the low sodium market, which is expected to grow exponentially, and that there is also scope to enter the larger salt market.

ENDS